TPG Capital is exploring a potential sale or IPO of Asia OneHealthcare, its portfolio hospital operator that could command a valuation as high as US$7.6 billion as private‑equity firms and strategic buyers pile into Southeast Asia’s fast‑growing healthcare sector. People familiar with the matter say the US buyout giant has begun preliminary discussions with investment banks about exit options, attracted by the group’s scale across Malaysia, Thailand and Vietnam and a broader M&A wave that has seen hospital valuations soar.
Asia OneHealthcare, formed through TPG’s 2019 acquisition of Malaysia’s Ramsay Sime Darby Medical, now operates 17 hospitals with over 3,000 beds and close to 2 million patient visits annually. The platform has grown revenue 25 per cent compounded since acquisition, driven by new greenfield developments, bed expansions and a shift toward higher‑acuity services such as oncology and cardiology. Adjusted EBITDA margins expanded to 22 per cent from 18 per cent, reflecting operational leverage and favourable reimbursement trends.
The timing reflects a perfect storm of tailwinds. Southeast Asia’s ageing populations, rising middle‑class incomes and patchy public‑health infrastructure are creating sustained demand for private care, with hospital occupancy rates averaging 75 per cent versus 65 per cent pre‑pandemic. Malaysia and Thailand lead medical tourism, while Vietnam’s urbanisation drives 12 per cent annual bed‑demand growth. TPG invested US$1.2 billion in expansions, adding 800 beds and seven new facilities.
Strategic buyers circle aggressively. Japan’s Mitsui & Co and Sumitomo Corp seek hospital footholds. Singapore’s IHH Healthcare eyes border expansion. Local champions like Malaysia’s KPJ and Thailand’s BGH plot counter‑offers. PE rivals such as CVC and KKR also express interest.
Valuation debates centre on 12–15 times EBITDA multiples, up from 8–10 times at acquisition. Comparable transactions include IHH’s Pantai acquisition at 13.5x and BGH’s 2025 IPO at 14.2x. Asia OneHealthcare’s diversified footprint and 90 per cent recurring revenue justify premium pricing.
Regulatory tailwinds support exits. Malaysia’s 100 per cent FDI in healthcare removes barriers. Singapore–Indonesia MoU streamlines cross‑border operations. Thailand’s medical tourism visas boost occupancy.
Risks temper enthusiasm. Medical inflation outpaces reimbursement 8 per cent annually. Nurse shortages hit 20 per cent vacancy rates. Geopolitical tensions disrupt expatriate patient flows.
TPG’s track record reassures investors. Previous exits include Fortis Healthcare (India) at 3x returns and Thomson Medical (Singapore). Asia OneHealthcare delivers 2.8x money multiple with two years IRR above 25 per cent. The potential transaction signals maturity in SEA healthcare PE. Early investors captured 10x returns on hospital build‑outs. Today’s scale platforms command institutional premiums. Successful exit catalyses next wave of digital health and ambulatory consolidation.
